Articles by Anna Rose Welch

71. Where Did The Biobetters Buzz Go? 4/2/2015

    The past few weeks, it seems the word on everyone’s tongue — including my own — has been biosimilars. Since the approval of Novartis’ Zarzio in the U.S., there’s been a lot of discussion and speculation about how this important approval will affect current blockbusters on the market and who will enter the space next. But I’m left with another question: What happened to the buzz over biobetters?

72. FDA, EMA Drug Approval Stats: Are We Measuring Success The Wrong Way? 3/27/2015

    While approval stats spark declarations of excitement from each regulatory agency and make news headlines, the differences in approval times in particular aren’t necessarily a cause for celebration; rather, they illuminate something much more concerning about the state of global drug development.

73. How Will AbbVie, J&J, And Amgen Handle The Biosimilar Age? 3/20/2015

    Following the approval of the first biosimilar last week, there were a number of questions circulating throughout the industry. My blog from last week addressed two questions about where the biosimilars market is headed, but I also wanted to address a third question I’ve seen cropping up: What are companies with blockbusters going to do to keep revenues intact now that they’re facing biosimilar competition?

74. Who To Watch In The Alzheimer's Treatment And Research Space 3/13/2015

    In an interview with the Triangle Business Journal, Eli Lilly CEO John Lechleiter said 2/3 of drugs fail to show efficacy in Phase 2 trials because there isn’t enough understanding of the targeted disease. He tells the Journal, “While drug hunting remains a vital activity… I think we need to advance, like our ancestors did, from hunting to farming, cultivating the knowledge of disease.”

75. FDA News Roundup: Bristol-Myers Squibb, Bayer, Astellas, And More 3/11/2015

    What FDA decisions have you missed in the last week?

76. FDA News Roundup: Shire, Bristol-Myers Squibb, Alexion, And More 3/6/2015

    What FDA decisions did you miss this week?

77. FDA News Roundup: Pfizer, Novartis, Sanofi, and More 3/2/2015

    What drug approvals have you missed recently?

78. 5 Trends Poised To Accelerate Drug Development 2/27/2015

    In November 2014, Tufts Center for Drug Discovery announced it takes $2.6 billion to push a drug through development and marketing approval — a process that often spans longer than 10 years.

79. Who Is Forging Ahead In The MS Treatment Space? 2/18/2015

    The NIH estimates roughly $103 million of its budget will be spent on multiple sclerosis research in 2015. That seems like a small amount of money when it comes to the size of its $40 billion budget.  But in doing some digging around, I’m seeing signs that there are actually quite a few players — big and small — in the academic, bio, and pharma realms working in the MS treatment space to benefit the 400,000 U.S. and 2.3 million patients globally.  

80. What's In Store For BioPharma R&D In 2015? 2/3/2015

    How the industry is tackling R&D these days is a hot topic, if traffic on this site is any indication. Last year, we posted a short feature about Lupin’s initiative to launch two new U.S. R&D centers. Looking at some numbers this week, it is still one of the top performing pieces on Bioprocess Online, which suggests to me the industry is itching to learn how companies are investing in the continuation of their pipelines.